Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

How Much Money Will Moderna Make From Its COVID Vaccine?

By Keith Speights - Dec 10, 2020 at 6:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Billions of dollars could soon pour into the biotech's coffers.

The countdown is on. One week from today, an FDA advisory committee will review Moderna's ( MRNA 6.42% ) emergency use authorization (EUA) filing for COVID-19 vaccine candidate mRNA-1273. The FDA will then make a final EUA decision soon thereafter, taking the advisory committee's recommendation into consideration. 

While anything can happen, it seems highly likely that mRNA-1273 will receive a green light from the FDA. That will pave the way for big bucks to begin flowing into Moderna's coffers. But just how much money will Moderna actually make from its COVID vaccine? 

Syringe with needle on top of $100 bills

Image source: Getty Images.

One analyst's projection

Bernstein analyst Ronny Gal recently stated that he expects the COVID-19 vaccine market will approach $40 billion in 2021. After that, he looks for the market to stabilize at roughly $6 billion per year.

Gal expects that Pfizer and BioNTech will generate the highest revenue with their messenger RNA (mRNA) vaccine BNT162b2. However, he views Moderna as a close No. 2 in the coronavirus vaccine market.

The analyst projects that Moderna will make $1.5 billion in the first quarter of 2021 from sales of mRNA-1273. Gal thinks that amount will rise to $3.5 billion by the third quarter. For the full year, he anticipates that Moderna will make around $11 billion. Over the next five years, Gal predicts that Moderna's sales of mRNA-1273 will approach $20 billion.

Will Ronny Gal's projection turn out to be right? Maybe. Wall Street analysts get paid to slice and dice all the available data to churn out solid estimates. There's no doubt that the $20 billion figure for Moderna reflects a lot of thought and careful analysis.

A wide range

However, it's important to understand that any analyst's project makes plenty of assumptions. In this case, for example, Gal assumes that Moderna will be able to produce 750 million doses of mRNA-1273 next year. Moderna has publicly stated that it expects to be able to make 500 million doses and up to 1 billion doses in 2021.

Gal also included an even more critical assumption in his projection. He predicts that booster vaccine shots will only be needed every three years. At this point, though, no one knows for sure how frequently booster shots will be required for COVID-19.

The reality is that there's a wide range of possibilities as to how much money Moderna might generate from mRNA-1273. If COVID vaccine booster shots are required annually rather than every three years, it would make a huge difference.

Let's suppose that annual boosters are needed. Also, assume that Moderna can make 750 million doses per year and sells all of them at the low end of its previously stated price range ($32 per dose). The company could make $24 billion each year in this scenario -- a lot more than Ronny Gal projects Moderna will make over the next five years.

Of course, there are other variables that could cause Moderna's take to be much lower. For example, if a single-dose vaccine with a high efficacy rate is launched, it could capture much of the market share from mRNA-1273. It's even possible (although I suspect unlikely) that Gal's three-year timeframe required for booster shots is overly pessimistic and that vaccines provide immunity for even longer periods.

Real money

The late U.S. Senator Everett Dirksen is attributed with saying, "A billion here, a billion there, and pretty soon you're talking real money." Regardless of exactly how much money Moderna makes from mRNA-1273, we'll likely soon be talking about real money for the company.

Probably the most important consequence of the potential cash influx that's on the way for Moderna is that it will be able to invest in its pipeline. Moderna's executives have thought for a long time that if its mRNA technology works with one disease, it will work with lots of diseases. 

Moderna's pipeline currently features 12 other mRNA therapeutic and vaccine candidates in clinical testing. With the billions of dollars it could soon receive, the company plans to expand its development to include up to 50 clinical-stage programs. 

Over the long run, it matters more what Moderna does with its cash than the specific amount that it makes. The good news for investors is the tremendous gains for the biotech stock could be just the beginning of a multi-year and even multi-decade climb if Moderna's mRNA approach works with other diseases as well as it appears to work with COVID-19.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$282.35 (6.42%) $17.02
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.72 (0.47%) $0.24
BioNTech SE Stock Quote
BioNTech SE
BNTX
$302.69 (8.17%) $22.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.